IDiyas

For the Inventor, By the Inventor

Seoul, South Korea

Gwang Pyo Ko

USPTO Granted Patents = 10 

 

Average Co-Inventor Count = 6.2

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:

goldMedal10 out of 13 
 
Kobiolabs, Inc.
 patents

Years Active: 2021-2025

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 12441979 - strain and use thereof (2025-10-14),
2. 12274718 - Composition and method for preventing, alleviating, or treating liver injury (2025-04-14),
3. 12070477 - sp. strain having ability to inhibit growth of vaginal pathogenic microorganisms (2024-08-27),
4. 11992511 - strain and use thereof (2024-05-28),
5. 11819526 - Lactobacillus Gasseri KBL697 strain and use thereof (2023-11-21),
6. 11633439 - Lactobacillus crispatus KBL693 strain and use thereof (2023-04-25),
7. 11602552 - Lactobacillus plantarum KBL396 strain and use thereof (2023-03-14),
8. 11291698 - strain and use thereof (2022-04-05),
9. 11285183 - KBL697 strain and use thereof (2022-03-29),
10. 11141444 - KBL693 strain and use thereof (2021-10-12),

Title: Innovations of Gwang Pyo Ko

Introduction

Gwang Pyo Ko is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of compositions for health-related applications. With a total of 10 patents to his name, his work focuses on addressing metabolic diseases and liver injuries.

Latest Patents

One of Gwang Pyo Ko's latest patents involves the SNUG-61027 strain, which is designed to suppress appetite and treat metabolic diseases. This invention includes a composition that comprises the strain or a culture solution, as well as a B2UM07 protein isolated from it. The patent outlines methods for using this composition to achieve weight reduction, regulate glucose homeostasis, and enhance the secretion of appetite-regulating hormones. Another significant patent addresses liver injury, specifically nonalcoholic fatty liver, by providing a composition aimed at preventing or treating such conditions.

Career Highlights

Gwang Pyo Ko is currently associated with Kobiolabs, Inc., where he continues to innovate in the field of biotechnology. His work has garnered attention for its potential impact on public health, particularly in combating obesity and liver-related diseases.

Collaborations

Gwang Pyo Ko collaborates with notable colleagues, including Tae-Wook Nam and Hyun Ju You. Their combined expertise contributes to the advancement of research and development in their respective fields.

Conclusion

Gwang Pyo Ko's contributions to biotechnology through his patents reflect his commitment to improving health outcomes. His innovative approaches to metabolic diseases and liver injuries position him as a key figure in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…